SCHEMBL13114591

SCHEMBL13114591

CC(C)(C)OC(=O)N1CCCC1C(=O)NN

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.58
NPC1 O15118 1/20 0.58
LMNA P02545 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HSD17B10 Q99714 1/20 0.56
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
ALDH1A1 P00352 1/20 0.52
SCN4A P35499 1/20 0.52
SCN5A Q14524 1/20 0.49
SCN3A Q9NY46 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.48
USP30 Q70CQ3 1/20 0.47
JAK2 O60674 1/20 0.46
KDM4E B2RXH2 2/20 0.46
UCHL1 P09936 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8237595 1.00 SMN1; SMN2 (0.58) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL6466465 1.00 SMN1; SMN2 (0.58) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL15746882 0.95 SMN1; SMN2 (0.54) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL15746874 0.95 SMN1; SMN2 (0.54) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL3554038 0.95 SMN1; SMN2 (0.54) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL26430066 0.91 SMN1; SMN2 (0.48) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL32691055 0.91 SMN1; SMN2 (0.48) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL30419080 0.91 SMN1; SMN2 (0.48) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL7422735 0.86 SMN1; SMN2 (0.60) SMN1; SMN2NPC1LMNANPSR1HSD17B10
SCHEMBL5403510 0.86 SMN1; SMN2 (0.60) SMN1; SMN2NPC1LMNANPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12103928-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2024-10-01 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
WO-2020138499-A1 ALKYL-SUBSTITUTED COMPOUND 大日本住友製薬株式会社 2020-07-02 WO disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
US-10544146-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2020-01-28 US disclosed
US-10150760-B2 Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor AMGEN INC. (US) 2018-12-11 US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 EP disclosed
US-8796257-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors NAEJA PHARMACEUTICAL INC. (CA) 2014-08-05 US disclosed
US-8796257-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors NAEJA PHARMACEUTICAL INC. (CA) 2014-08-05 US disclosed
EP-2748165-A1 1,6- DIAZABICYCLO [3,2,1]OCTAN-7-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS Wockhardt Limited (IN) 2014-07-02 EP disclosed
WO-2014091268-A1 NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2014-06-19 WO disclosed
WO-2013131018-A1 BIARYL INHIBITORS OF THE SODIUM CHANNEL ZALICUS PHARMACEUTICALS LTD. (US) 2013-09-06 WO disclosed
WO-2013030733-A1 1,6- DIAZABICYCLO [3,2,1] OCTAN-7-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS WOCKHARDT LIMITED (IN) 2013-03-07 WO disclosed
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-10544146-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors NR0B1, NR2E1, NR0B2 SMN1; SMN2 2477/4885NPC1 1654/4885LMNA 2292/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB SMN1; SMN2 2493/4885NPC1 1651/4885LMNA 1112/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-12103928-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-10150760-B2 Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor TBXA2R, APLNR, GPR27 SMN1; SMN2 4831/4885NPC1 2857/4885LMNA 2922/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 SMN1; SMN2 702/4885NPC1 903/4885LMNA 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.